A "middle-out" approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 41, Issue 3, 2014, Pages 197-209

  Li, Rui ^a   Barton, Hugh A ^a   Yates, Phillip D ^a   Ghosh, Avijit ^a   Wolford, Angela C ^a   Riccardi, Keith A ^a   Maurer, Tristan S ^a  

^a PFIZER INC   (United States)

Author keywords

Global optimization; Middle out; OATP; PBPK; Sandwich cultured human hepatocytes; Scaling factor

Indexed keywords

BOSENTAN; CERIVASTATIN; FLUINDOSTATIN; ORGANIC ANION TRANSPORTER; PRAVASTATIN; REPAGLINIDE; ROSUVASTATIN; VALSARTAN;

ARTICLE; DRUG RESEARCH; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MATHEMATICAL ANALYSIS; PERMEABILITY; PHARMACOKINETICS; PHYSIOLOGICAL PROCESS; PHYSIOLOGICALLY BASED PHARMACOKINETIC; PREDICTIVE VALUE; PRIORITY JOURNAL; RATING SCALE; ALGORITHM; CELL CULTURE; CONFIDENCE INTERVAL; LIVER CELL; METABOLISM; STATISTICAL MODEL;

ALGORITHMS; CELLS, CULTURED; CONFIDENCE INTERVALS; HEPATOCYTES; HUMANS; MODELS, STATISTICAL; ORGANIC ANION TRANSPORTERS; PHARMACOKINETICS;

EID: 84904201004     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-014-9357-1     Document Type: Article

References (22)

1. Rowland M, Peck C, Tucker G (2011) Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 51:45-73. doi:10.1146/annurev-pharmtox-010510-100540
2. Jones HM, Gardner IB, Collard WT, Stanley PJ, Oxley P, Hosea NA, Plowchalk D, Gernhardt S, Lin J, Dickins M, Rahavendran SR, Jones BC, Watson KJ, Pertinez H, Kumar V, Cole S (2011) Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling. Clin Pharmacokinet 50(5):331-347. doi:10.2165/11539680-000000000-00000
3. Jones HM, Parrott N, Jorga K, Lave T (2006) A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 45(5):511-542. doi:10.2165/00003088-200645050-00006
4. De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA (2007) Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 35(10):1766-1780. doi:10.1124/dmd.107.015644 (Pubitemid 47481568)
5. Rostami-Hodjegan A, Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6(2):140-148. doi:10.1038/nrd2173 (Pubitemid 46745341)
6. Poirier A, Cascais AC, Funk C, Lave T (2009) Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. J Pharmacokinet Pharmacodyn 36(6):585-611. doi:10.1007/s10928-009-9139-3
7. Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y (2009) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328(2):652-662. doi:10.1124/jpet.108.146647
8. Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, Sugiyama Y (2010) Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos 38(2):215-222. doi:10.1124/dmd.109.030254
9. Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston JB, Galetin A, Fenner KS (2012) Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos 40(5):1007-1017. doi:10.1124/dmd.111.042994
10. Tsamandouras N, Rostami-Hodjegan A, Aarons L (2013) Combining the "bottom-up" and "top-down" approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. Br J Clin Pharmacol. doi:10.1111/bcp.12234
11. Rodgers T, Rowland M (2006) Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95(6):1238-1257. doi:10.1002/jps.20502 (Pubitemid 43874439)
12. Vanlier J, Tiemann CA, Hilbers PA, van Riel NA (2012) An integrated strategy for prediction uncertainty analysis. Bioinformatics 28(8):1130-1135. doi:10.1093/bioinformatics/bts088
13. Shah DK, Betts AM (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39(1):67-86. doi:10.1007/s10928- 011-9232-2
14. Kalvass JC, Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23(8):327-338. doi:10.1002/bdd.325 (Pubitemid 36124162)
15. Seber GAF, Wild CJ (2003) Nonlinear regression., Wiley series in probability and statisticsWiley-Interscience, Hoboken
16. Thai HT, Mentre F, Holford NH, Veyrat-Follet C, Comets E (2013) A comparison of bootstrap approaches for estimating uncertainty of parameters in linear mixed-effects models. Pharm Stat 12(3):129-140. doi:10.1002/pst.1561
17. Poirier A, Cascais AC, Funk C, Lave T (2009) Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data. Chem Biodivers 6(11):1975-1987. doi:10.1002/cbdv. 200900116
18. Varma MV, Lai Y, Kimoto E, Goosen TC, El-Kattan AF, Kumar V (2013) Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide. Pharm Res 30(4):1188-1199. doi:10.1007/s11095-012- 0956-5
19. Jamei M, Bajot F, Neuhoff S, Barter Z, Yang J, Rostami-Hodjegan A, Rowland-Yeo K (2014) A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine. Clin Pharmacokinet 53(1):73-87. doi:10.1007/s40262-013-0097-y
20. Tomita Y, Maeda K, Sugiyama Y (2013) Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism. Clin Pharmacol Ther 94(1):37-51. doi:10.1038/clpt.2012.221
21. Kalliokoski A, Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158(3):693-705. doi:10.1111/j.1476-5381.2009. 00430.x
22. Kitamura S, Maeda K, Wang Y, Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36(10):2014-2023. doi:10.1124/dmd.108.021410